Business Context and Reporting Period
This Form 8-K filing by Vanda Pharmaceuticals Inc. reports on executive compensation actions taken by the Compensation Committee on December 4, 2014. The report covers the approval of 2014 annual bonuses, the establishment of 2015 base salaries and bonus targets, and the granting of equity incentives to named executive officers.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on executive compensation figures:
- 2014 Bonuses Awarded: Total of $795,000 distributed among three executives.
- 2015 Base Salaries: Total annualized base salary of $1,350,000 for the three executives.
- 2015 Bonus Targets: Set as percentages of base salary (60% for CEO, 40% for SVPs).
- Equity Grants: Options granted at an exercise price of $12.27 per share.
Material Changes and Compensation Details
The filing details specific compensation adjustments for the following officers:
| Officer | Position | 2014 Bonus | 2015 Base Salary | 2015 Target Bonus | Option Grant | RSU Grant |
|---|---|---|---|---|---|---|
| Mihael Polymeropoulos, M.D. | President and CEO | $435,000 | $600,000 | 60% of Base | 150,000 | 50,000 |
| Paolo Baroldi, M.D. | SVP and CMO | $180,000 | $375,000 | 40% of Base | 60,000 | 20,000 |
| James Kelly | SVP and CFO | $180,000 | $375,000 | 40% of Base | 60,000 | 20,000 |
Equity Vesting Terms: Options vest in equal monthly installments over four years. Restricted Stock Units (RSUs) vest in four equal annual installments beginning January 1, 2016.
Management Commentary and Risks
The Compensation Committee reviewed an analysis of executive compensation relative to a peer group conducted by Towers Watson prior to approving these awards. The filing does not contain specific guidance, outlook, or risk factors beyond the standard vesting schedules and performance periods associated with the compensation packages.
Key Facts for Investor Verification
- Verify the total cash outflow for 2014 bonuses ($795,000) against the company's cash position in the most recent 10-Q or 10-K.
- Confirm the dilution impact of the 330,000 option shares and 90,000 RSU shares granted.
- Review the 2015 bonus target percentages to understand potential future cash compensation liabilities.
- Check the stock price performance relative to the $12.27 exercise price to assess the intrinsic value of the option grants.